|
WO2021067266A1
|
|
Pyrrolidinyl-based compounds
|
|
WO2021030401A1
|
|
Process for making [1.1.1] propellane
|
|
US2021038573A1
|
|
Estrogen receptor modulators for treating mutants
|
|
WO2021007303A1
|
|
Nanoparticle formulation of bcl-2 inhibitor
|
|
WO2021007307A1
|
|
Bcl-2 protein inhibitors
|
|
WO2020210320A1
|
|
Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
|
|
SG11202006906XA
|
|
Substituted 1,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones
|
|
CA3087262A1
|
|
Benzamide compounds
|
|
CA3074073A1
|
|
Continuous flow processes for making bicyclic compounds
|
|
CN111094253A
|
|
1, 2-dihydro-3H-pyrazolo [3,4-d ] pyrimidin-3-one analogs
|
|
US2021094899A1
|
|
Acrylic acid analogs
|
|
AU2018269755A1
|
|
Analgesic compounds
|
|
AU2017339890A1
|
|
Spirocyclic compounds
|
|
EP3442971A1
|
|
Estrogen receptor modulators
|
|
US2019111031A1
|
|
Analgesic compounds
|
